Last reviewed · How we verify
Polyethylene Glycol Ointment [Placebo]
Polyethylene glycol ointment is an inert, occlusive topical vehicle that provides no active pharmacological effect and serves as a placebo control.
Polyethylene glycol ointment is an inert, occlusive topical vehicle that provides no active pharmacological effect and serves as a placebo control. Used for Placebo control in clinical trials.
At a glance
| Generic name | Polyethylene Glycol Ointment [Placebo] |
|---|---|
| Also known as | PEG Ointment |
| Sponsor | US Department of Veterans Affairs |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo formulation, polyethylene glycol ointment contains no active pharmaceutical ingredient and exerts no therapeutic mechanism of action. It is used in clinical trials as a control comparator to assess the efficacy of active treatments by accounting for placebo effects. The ointment base itself may provide minimal skin hydration through occlusion, but this is not considered a therapeutic mechanism.
Approved indications
- Placebo control in clinical trials
Common side effects
- Skin irritation or sensitization to ointment base
- Local erythema or contact dermatitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: